Abstract
Cancer stem cells (CSCs) were identified in human leukemias in landmark studies of John Dick and his colleagues. Subsequently, similar cancer stem-like cells were identified in solid tumors of the breast, colon, brain and other sites. CSCs have distinct markers and are highly tumorigenic compared to other subsets. They can differentiate into all the cell phenotypes of the parental tumor. Other key features include activation of pluripotency genes (Oct4, Sox2, Nanog), self-renewal, formation of tumor spheres in low-adherence cultures, and multi-drug resistance. Clinically, drug resistance is probably the most important feature, because CSCs resist conventional cancer therapies and are likely to play a major role in cancer relapse. Based on their properties, several molecules have been targeted for therapy with drugs as follows. 1) The self-renewal pathways Wnt/β-catenin, Hedgehog and Notch. 2) The aryl hydrocarbon receptor (AHR), with tranilast and other AHR agonists. 3) Cytokines and inflammatory pathways (e.g., IL-6, IL-8, NF-κB). 4) TGF-β and epithelial- to-mesenchymal transition (EMT) pathways. 5) Homing molecules involved in metastasis; most notably CXCR4 or its ligand CXCL12. 6) Growth factors, their receptors and coreceptors (such as neuropilin-1), and signaling components (e.g., tyrosine kinases). 7) Cell-surface markers (CD44 and integrins). Several drugs have been identified by screening or other observations (salinomycin, metformin, tesmilifene, sulforaphane, curcumin, piperine and others). Some of these drugs are at preclinical or early clinical phases of development, and it remains to be seen how many will progress to clinical application. This review focuses on some promising new developments in anti-CSC drug therapy.
Keywords: Aryl hydrocarbon receptor, cancer stem cell, epithelial-to-mesenchymal transition, mammosphere, neuropilin, Oct4, transforming growth factor beta, tranilast, anti-CSC drug therapy
Current Pharmaceutical Design
Title:Cancer Stem Cells and Novel Targets for Antitumor Strategies
Volume: 18 Issue: 19
Author(s): Gerald J. Prud’homme
Affiliation:
Keywords: Aryl hydrocarbon receptor, cancer stem cell, epithelial-to-mesenchymal transition, mammosphere, neuropilin, Oct4, transforming growth factor beta, tranilast, anti-CSC drug therapy
Abstract: Cancer stem cells (CSCs) were identified in human leukemias in landmark studies of John Dick and his colleagues. Subsequently, similar cancer stem-like cells were identified in solid tumors of the breast, colon, brain and other sites. CSCs have distinct markers and are highly tumorigenic compared to other subsets. They can differentiate into all the cell phenotypes of the parental tumor. Other key features include activation of pluripotency genes (Oct4, Sox2, Nanog), self-renewal, formation of tumor spheres in low-adherence cultures, and multi-drug resistance. Clinically, drug resistance is probably the most important feature, because CSCs resist conventional cancer therapies and are likely to play a major role in cancer relapse. Based on their properties, several molecules have been targeted for therapy with drugs as follows. 1) The self-renewal pathways Wnt/β-catenin, Hedgehog and Notch. 2) The aryl hydrocarbon receptor (AHR), with tranilast and other AHR agonists. 3) Cytokines and inflammatory pathways (e.g., IL-6, IL-8, NF-κB). 4) TGF-β and epithelial- to-mesenchymal transition (EMT) pathways. 5) Homing molecules involved in metastasis; most notably CXCR4 or its ligand CXCL12. 6) Growth factors, their receptors and coreceptors (such as neuropilin-1), and signaling components (e.g., tyrosine kinases). 7) Cell-surface markers (CD44 and integrins). Several drugs have been identified by screening or other observations (salinomycin, metformin, tesmilifene, sulforaphane, curcumin, piperine and others). Some of these drugs are at preclinical or early clinical phases of development, and it remains to be seen how many will progress to clinical application. This review focuses on some promising new developments in anti-CSC drug therapy.
Export Options
About this article
Cite this article as:
J. Prud’homme Gerald, Cancer Stem Cells and Novel Targets for Antitumor Strategies, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626120
DOI https://dx.doi.org/10.2174/138161212800626120 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation and Parkinsons Disease
Current Drug Targets - Inflammation & Allergy Innate Immune Receptors and IRF Family Transcription Factors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Studies on the Biotransformations and Biodistributions of Metal-Containing Drugs Using X-Ray Absorption Spectroscopy
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Natural Leads in Drug Discovery against Metabolic Disorders and their Related Infectious Diseases)
Current Topics in Medicinal Chemistry The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets Thrombosis and Nephrotic Syndrome in Children
Current Pediatric Reviews A Chemo-Enzymatic Approach to Some Indole and Quinolizidine Alkaloids From Cs -Symmetric Precursors
Current Organic Chemistry Role of Formyl Peptide Receptors (FPR) in Abnormal Inflammation Responses Involved in Neurodegenerative Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Aptamer-Targeted Oligonucleotide Theranostics: A Smarter Approach for Brain Delivery and the Treatment of Neurological Diseases
Current Topics in Medicinal Chemistry Recent Advances in Immunotherapy for Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Effects of Vaccination Against the H1N1 Virus on BDNF and TNF-α Plasma Levels in Pregnant Women
Current Drug Safety Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy Inflammatory Reactions and Hydrocortisone in the Setting of Cardiac Surgery: An Overview
Cardiovascular & Hematological Agents in Medicinal Chemistry Inflammation in Fish As Seen from A Morphological Point of View with Special Reference to the Vascular Compartment
Current Pharmaceutical Design Recent Developments in the Search for Biomarkers for the Diagnosis and Monitoring of Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Aspirin Induced Adverse Effects on the Small and Large Intestine
Current Pharmaceutical Design Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology
Current Pharmaceutical Design DNA Vaccines for Prostate Cancer
Current Cancer Therapy Reviews